Apitegromab for lean mass preservation during tirzepatide-induced weight loss: a randomized, double-blind, placebo-controlled phase 2 trial
Richard E. Pratley / nature - Nature Medicine, Published online: 08 June 2026; doi:10.1038/s41591-026-04440-4In the phase 2 EMBRAZE study, participants receiving tirzepatide and apitegromab lost less lean mass compared to participants receiving tirzepatide and placebo.
AI Summary: A randomized, double‑blind phase 2 trial found apitegromab helped preserve lean mass in people losing weight on tirzepatide (a GLP‑1–class obesity medication). The drug reduced treatment‑associated muscle wasting without undermining weight loss, positioning apitegromab as a potential adjunct for patients worried about strength and frailty during aggressive metabolic therapy.
NRG-GY018 at ASCO 2026: Pembrolizumab Plus Chemotherapy Sustains Overall Survival Benefit in Advanced Endometrial Cancer
oncodaily - The NRG-GY018 trial returned to the ASCO 2026 stage with the question that matters more than any progression endpoint: do patients actually live longer? Presented by Ramez N. Eskander, MD […]
AI Summary: Updated results from the NRG‑GY018 trial show adding pembrolizumab to chemotherapy sustains an overall survival benefit in advanced endometrial cancer. The follow‑up confirms the durability of immunotherapy’s impact and supports integrating checkpoint inhibitors into standard regimens for eligible patients, potentially changing practice for a cancer type that’s long hungered for better systemic options.
Some tumors eliminate healthy neighboring cells to grow, study reveals
medicalxpress - Chromosomal instability is a common feature in many solid tumors and is associated with greater aggressiveness. For years, its main contribution to cancer was thought to be driving the evolution of tumor genomes, causing cells to gain chromosomes with gro…
AI Summary: Researchers found some tumors actively eliminate neighboring healthy cells to expand and thrive, revealing a brutal but precise survival strategy. Understanding the molecular signals that drive this local cell clearance exposes new therapeutic targets — flip the mechanism and you may stop tumors in their tracks, or at least make cancer's arrogance its downfall.
First AI-designed 'universal vaccine' tested in humans: UK researchers
medicalxpress - A vaccine targeting a broad range of viruses that was designed using artificial intelligence had a "modest" effect on immune systems in a small, early trial, according to a new study.
AI Summary: UK researchers have initiated the first human trial of a vaccine designed using artificial intelligence, aiming for broad protection beyond conventional strain-specific shots. Early-phase testing focuses on safety and immune responses, marking a novel fusion of machine learning and immunology that could speed vaccine design — if the algorithms behave.
15-strain live biotherapeutic product or same donor fecal microbiota transplant for recurrent Clostridioides difficile infection: a randomized phase 1b trial
Lukas Bethlehem / nature - Nature Medicine, Published online: 02 June 2026; doi:10.1038/s41591-026-04442-2A randomized, single-blind, parallel-group, phase 1b clinical trial compared fecal microbiota transplant or a 15-strain live biotherapeutic product (MTC01) derived from the sam…
AI Summary: A randomized phase 1b trial compared a defined 15‑strain live biotherapeutic product with traditional donor fecal microbiota transplant for recurrent Clostridioides difficile infection and found comparable safety and efficacy. The result supports a manufactured, standardized microbiome therapy as a realistic alternative to donor stool, simplifying logistics and regulation — and making “poop pills” slightly less artisanal.
FDA Approves Oral Combination of Decitabine and Cedazuridine Tablets with Venetoclax for Newly Diagnosed AML
esmo - Evidence for efficacy is based on the results from the Study ASTX727-07
AI Summary: The FDA has approved an oral combination (decitabine/cedazuridine plus venetoclax) as a treatment option for newly diagnosed acute myeloid leukemia patients who are older or unfit for intensive therapy. The approval offers an at-home alternative to frequent infusions, potentially reducing clinic visits and improving convenience for a vulnerable population.
- Experts celebrate all-oral AML option online (3)
- FDA approval and ASCERTAIN V trial evidence (3)
- Targeted therapies and regimen optimization in AML (3)
Experts celebrate all-oral AML option online
FDA approval and ASCERTAIN V trial evidence
Targeted therapies and regimen optimization in AML
Eli Lilly's ultimatum to hospitals: Send 340B claims data by June 1 or lose discounts
fiercehealthcare - The drugmaker has issued a June 1 ultimatum to an unspecified number of hospitals that have resisted a data submission policy it implemented in February. Furious hospital industry groups are pushing back, calling the decision unlawful and urging the admin…
AI Summary: Eli Lilly has given hospitals an ultimatum: submit 340B claims data within a tight deadline or lose drug discounts. The move pressures health systems to comply quickly, raising questions about administrative burden, data-sharing logistics and potential financial strain for safety-net providers that rely on the program’s savings.
PROTEUS Trial at ASCO 2026: Perioperative Apalutamide Plus ADT in high-risk localized or locally advanced prostate cancer
oncodaily - PROTEUS trial, was presented during the ASCO 2026 Plenary Session by Mary-Ellen Taplin, MD, FASCO. The study evaluated one year of perioperative apalutamide plus androgen deprivation therapy in patients with […]
AI Summary: A perioperative strategy adding apalutamide to androgen‑deprivation therapy around radical prostatectomy shows improved outcomes for men with high‑risk or locally advanced prostate cancer, reducing metastasis and disease‑related death. Findings were highlighted and debated at ASCO sessions, prompting discussion about changing perioperative standards — and yes, surgeons are already updating their talking points.
- Industry, webinars and social media amplification of ASCO results (3)
- On-the-ground clinician reaction and emerging cN1 debate (3)
- PROTEUS trial: perioperative apalutamide reduces metastasis and death (3)
Industry, webinars and social media amplification of ASCO results
On-the-ground clinician reaction and emerging cN1 debate
PROTEUS trial: perioperative apalutamide reduces metastasis and death
GLP-1 use linked to lower breast cancer incidence in large cohort study
medicalxpress - A retrospective analysis of more than 110,000 women between the ages of 45 and 80 found that those who took GLP-1 medications were about 30% less likely to develop breast cancer than those who did not take GLP-1 medications, according to research presente…
AI Summary: A large observational cohort study reported an association between GLP‑1 agonist use and a lower incidence of breast cancer. The result is intriguing and may spur biological investigation, but researchers caution against causal claims—confounding and indication bias mean randomized trials would be required to confirm any protective effect.
LIBRETTO-432 Trial at ASCO 2026 Plenary Session: Adjuvant Selpercatinib in RET Fusion-Positive NSCLC
oncodaily - LIBRETTO-432 Trial was presented during ASCO 2026 by Jonathan W. Goldman, MD, as a global, multicenter, phase 3, double-blind, randomized, placebo-controlled study evaluating adjuvant selpercatinib in patients with early-stage RET […]
AI Summary: At ASCO26 plenary, LIBRETTO‑432 data show adjuvant selpercatinib markedly prolongs event‑free survival and slashes recurrence risk for patients with stage II–IIIA RET fusion–positive non‑small cell lung cancer after curative treatment. The findings support a new standard for this rare genetic subgroup and press the case for routine genomic testing.
Zanidatamab Plus Chemotherapy Prolongs PFS Over Trastuzumab Plus Chemotherapy in Patients with HER2-positive Advanced Gastro-Oesophageal Adenocarcinoma
esmo - Findings from the HERIZON-GEA-01 study
AI Summary: A phase 3 readout from the HERIZON‑GEA‑01 program shows zanidatamab plus chemotherapy prolongs progression‑free survival compared with trastuzumab plus chemotherapy in HER2‑positive advanced gastro‑oesophageal adenocarcinoma. The data, now published and debated at ASCO, also probes whether adding anti‑PD‑1 therapy (tislelizumab) meaningfully changes outcomes — promising for a tough cancer, if you like incremental revolutions.
Florida hospitals lose $2B opioid lawsuit against pharmacies
Ella Jeffries / beckershospitalreview - A Florida judge has ruled in favor of CVS, Walgreens and Walmart in a lawsuit brought by 16 hospitals seeking $2 billion in damages related to the opioid epidemic. Broward County Chief Judge Carol-Lisa Phillips entered judgment for the defendants May 26, …
AI Summary: A Florida court ruling overturned a multibillion‑dollar claim by hospitals against major pharmacy chains, finding in favor of CVS, Walgreens and Walmart in litigation tied to the opioid epidemic. The decision removes a major anticipated payout and reshapes liability questions in the national effort to hold corporate actors accountable for addiction harms — legal teams are predictably thrilled.
One-time gene editing treatment lowers 'bad' cholesterol by up to 62%
medicalxpress - Patients in London have received a pioneering new gene editing therapy that lowers "bad" cholesterol after a single infusion, as part of a study involving UCL scientists.
AI Summary: Early clinical data show a one‑time gene‑editing infusion can reduce LDL cholesterol by as much as 62% in patients with severe hypercholesterolemia. The approach, still experimental, produced large lipid drops with early safety signals, hinting at a possible future one‑and‑done therapy for high‑risk cardiovascular patients — pending larger trials and careful long‑term follow‑up.
MAGE-A4/MAGE-A8-targeted TCR-based bispecific T cell engager in recurrent and/or refractory solid tumors: a phase 1 trial
Martin Wermke / nature - Nature Medicine, Published online: 31 May 2026; doi:10.1038/s41591-026-04455-xAs presented at the 2026 ASCO Annual Meeting, in a prespecified interim analysis of a phase 1a trial of IMA401—a new bispecific TCR-based T cell engager that binds a MAGE-A4/MAG…
AI Summary: A phase 1 trial of a TCR‑based bispecific T‑cell engager targeting MAGE‑A4 and MAGE‑A8 demonstrated early anti‑tumor activity in recurrent or refractory solid tumors, with an acceptable safety profile in dose‑finding cohorts. These results revive interest in targeting intracellular cancer antigens via T‑cell redirection, nudging immunotherapy beyond familiar checkpoint territory.
RASolute 302 Trial at ASCO 2026 Plennary Session: Daraxonrasib Improves Survival Versus Chemotherapy in Previously Treated Metastatic PDAC
oncodaily - RASolute 302 Trial was presented by Brian M. Wolpin, MD, MPH, during the 2026 ASCO Annual Meeting.The Trial evaluated daraxonrasib, an oral RAS(ON) multi-selective inhibitor, against investigator’s choice chemotherapy in […]
AI Summary: A plenary ASCO presentation reports daraxonrasib, an oral KRAS G12C inhibitor, significantly improved overall survival compared with chemotherapy in previously treated metastatic pancreatic ductal adenocarcinoma. The data prompted immediate planning across cancer centers for anticipated demand and access changes — a rare dose of good news for a disease that usually gets none.
Pfizer’s $10.5B Deal With One of China’s Top Cancer Biotechs Is Another Sign the Game is Changing
Frank Vinluan / medcitynews - Pfizer unveiled a multi-drug R&D collaboration with Innovent Biologics, making it the latest big pharma company to reach a deal that taps into Chinese labs to source biotech innovation. This alliance will focus on developing next-generation drugs in the c…
AI Summary: Pfizer struck a $10.5 billion deal to acquire a leading Chinese oncology biotech, a transaction industry watchers say underlines China’s accelerating drug‑development muscle. Analysts flagged broader implications for global R&D competition, partnerships and where future oncology innovation — and manufacturing heft — might live.
DESTINY-Lung03: T-DXd Confirms Activity in HER2-Overexpressing NSCLC, but Triplet Therapy Falls Short
oncodaily - DESTINY-Lung03 Part 1 provides an important signal for the treatment of HER2-overexpressing non-small cell lung cancer (NSCLC). The study confirms that trastuzumab deruxtecan (T-DXd) monotherapy has clinically meaningful activity in […]
AI Summary: DESTINY‑Lung03 data confirmed trastuzumab deruxtecan has tangible activity in HER2‑overexpressing non‑small‑cell lung cancer, producing notable responses. Attempts to escalate to triplet regimens failed to add benefit, prompting a reality check on combination complexity and the need for sharper biomarkers rather than more drugs.
Listen to the Latest ‘KFF Health News Minute’
kffhealthnews - The "KFF Health News Minute" brings original health care and health policy reporting from our newsroom to the airwaves each week.
AI Summary: A phase 2 study investigated FGFR inhibition with rogaratinib in succinate dehydrogenase–deficient gastrointestinal stromal tumors. Results reported tumor control in this rare molecular subset, offering a targeted therapeutic approach where options are sparse and validating FGFR as a biologic vulnerability in SDH‑deficient GIST.
MajesTEC-9 Results at ASCO 2026: Teclistamab Monotherapy Demonstrates Superiority Over PVd/Kd in Earlier-Line RRMM
oncodaily - At ASCO 2026, results from MajesTEC-9 (NCT05572515), the first phase 3 study of teclistamab monotherapy in patients with relapsed or refractory multiple myeloma (RRMM) after 1-3 prior lines of therapy, […]
AI Summary: Teclistamab monotherapy demonstrated superior progression-free survival and response rates versus pomalidomide‑based (PVd) and carfilzomib‑based (Kd) regimens in earlier-line relapsed/refractory multiple myeloma, showing durable remissions at 18 months. The data suggest a shift toward bispecific antibody therapy earlier in the treatment sequence for many patients.
- ASCO social media: expert reactions and highlights (4)
- MajesTEC‑9: Teclistamab outperforms PVd/Kd (4)
- Other BCMA and novel myeloma immunotherapies at ASCO (3)
- All Other Stories
ASCO social media: expert reactions and highlights
MajesTEC‑9: Teclistamab outperforms PVd/Kd
Other BCMA and novel myeloma immunotherapies at ASCO
All Other Stories
FDA Approves Decnupaz (pivekimab sunirine-pvzy), the First ADC for Adults With BPDCN
oncodaily - On May 27, 2026, the U.S. FDA granted approval to pivekimab sunirine-pvzy (Decnupaz, AbbVie, Inc.), a CD123-directed antibody and alkylating agent conjugate, for the treatment of adults with blastic plasmacytoid […]
AI Summary: The FDA approved pivekimab sunirine (Decnupaz/pvzy), the first antibody‑drug conjugate for blastic plasmacytoid dendritic cell neoplasm (BPDCN), marking a regulatory win for an ultra‑rare blood cancer. The decision underscores ADCs’ growing role in niche hematologic malignancies and anchors AbbVie’s expanding ADC strategy.
- ASCO 2026: ADC education, efficacy signals, and ocular toxicity (4)
- Decnupaz approval reshapes BPDCN treatment landscape (4)
- Real-world ADC safety: infection risks and rechallenge questions (3)